Harashima, S., Inagaki, N., Kondo, K., Maruyama, N., Otsuka, M., Kawaguchi, Y., & Watanabe, Y. (2018). Efficacy and safety of canagliflozin as add‐on therapy to a glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week, open‐label, phase IV study. Diabetes Obes Metab.

Harashima, Shin‐ichi, Nobuya Inagaki, Kazuoki Kondo, Nobuko Maruyama, Makiko Otsuka, Yutaka Kawaguchi, and Yumi Watanabe. "Efficacy and Safety of Canagliflozin As Add‐on Therapy to a Glucagon‐like Peptide‐1 Receptor Agonist in Japanese Patients With Type 2 Diabetes Mellitus: A 52‐week, Open‐label, Phase IV Study." Diabetes Obes Metab 2018.

Harashima, Shin‐ichi, et al. "Efficacy and Safety of Canagliflozin As Add‐on Therapy to a Glucagon‐like Peptide‐1 Receptor Agonist in Japanese Patients With Type 2 Diabetes Mellitus: A 52‐week, Open‐label, Phase IV Study." Diabetes Obes Metab 2018.